Molecular Diagnostics Market By Application (Oncology, Genetic Tests, Infectious Diseases, Micro Biology, Blood Screening), By Product (Software & Services, Reagent, Instruments), By Technology (Isothermal Nucleic Acid Amplification, Hybrization, Polymerase Chain Reaction, DNA Sequencing And Next-Generation Sequencing, Microarrays), By End User (Reference Laboratories, Hospital/Academic Laboratories), Industry Size, Growth, Share And Forecast To 2022

Published By: Brisk Insights | Published On: Mar 17, 2016

Key Findings


The global molecular diagnostics market is expected to grow at the CAGR of 21.3% during 2015-2022. The major factors driving the market are increasing demand for personalized care facilities and rising prevalence rate of infectious diseases. Increase in geriatric population has also contributed significantly in the growth of molecular devices market. These devices help in detecting genetic disorders, infectious diseases, and cancer at early stage. Recent advancements in technology have enabled devices to provide accurate and fast results. This feature of diagnostic devices has led to the growth of penetration levels in terms of personalized care facilities. Favorable regulatory initiatives with the aim of promoting personalized care diagnosis over other forms is anticipated as a high impacting key driver in this market. In U.S., Clinical Laboratory Improvement Amendments are initiated which is anticipated to uplift usage rates over the forecasted period. Although there are many factors driving the market yet there are some challenges faced by the market such as high price of tests, time consuming while using micro-arrays based devices and presence of complex regulatory framework.


Market Segment Insight


The market is majorly segmented on the basis of application, products & services, technology and end users. On the basis of application the market is segmented into oncology, genetic tests, infectious diseases, microbiology, blood screening and others. Infectious diseases dominate the molecular diagnostics market and contribute around 50% revenue in 2015. Oncology is expected to witness significant growth during the forecasted period. It is further segmented on the basis of products and services including software and services, reagents and instruments. Reagents dominate the market by contributing highest in terms of revenue. On the basis of technology, molecular diagnostics is bifurcated into isothermal nucleic acid amplification technology, hybridization, polymerase chain reaction, microarrays, DNA sequencing and next-generation sequencing and other technologies. Polymerase chain reaction contributes significantly to the growth of the growth if molecular diagnostics market. It can also be segmented on the basis of end users including software & services, reagents and instruments


Regional Insight


Globally, the molecular diagnostics market is segmented into North America, Europe, APAC, Middle East & Africa, Latin America and RoW. North America has the largest market share of molecular diagnostics followed by Asia Pacific. Increasing investments in R&D by large biotechnological and pharmaceutical companies, demand for personalized care at early stage, availability of sophisticated healthcare infrastructure along with penetration in technological advancements are the key factors behind the growth of this region. Asia Pacific is estimated to witness significant growth over the forecasted period due to increasing prevalence of infectious and cardiovascular diseases and rising health awareness.


Competitive Insights


Some of the key market players are Abbott laboratories, Bio-Rad Laboratories, Alere Inc., Becton Dickinson, Cephid, Siemens Healthcare, Sysmex Corporation and Roche Diagnostics, etc. Acquisitions, new product development, collaborations, joint ventures, mergers and expansions are the key strategies adopted by the market players to sustain in the market.

CHAP 1. METHODOLOGY & SCOPE 13
    1.1. RESEARCH METHODOLOGY 13
    1.2. RESEARCH SCOPE & ASSUMPTIONS 13
    1.3. LIST OF DATA SOURCES 13


CHAP 2. EXECUTIVE SUMMARY 14
    2.1. GLOBAL MOLECULAR DIAGNOSTICS MARKET SUMMARY & KEY BUYING CRITERIA 14
    2.2. GLOBAL MOLECULAR DIAGNOSTICS MARKET OUTLOOK 14
    2.3. MARKET SEGMENTATION ANALYSIS 14
    2.4. MARKET SIZE AND GROWTH PROSPECTS 2012-2022 14
    2.5. GLOBAL MOLECULAR DIAGNOSTICS MARKET VALUE CHAIN ANALYSIS 14
    2.6. VENDOR LANDSCAPE 14


CHAP 3. GLOBAL MOLECULAR DIAGNOSTICS MARKET 15
    3.1. MARKET DRIVER ANALYSIS 15
        3.1.1. INCREASING GERIATRIC POPULATION 15
        3.1.2. RISING PREVALENCE RATE OF TYPES OF CANCER AND INFECTIOUS DISEASES 15
        3.1.3. PROTEOMICS & GENOMICS RESEARCH AT GROWTH STAGE 15
        3.1.4. INCREASE IN DEMAND FOR PERSONALIZED CARE FACILITIES 15
    3.2. MARKET RESTRAINT ANALYSIS 15
        3.2.1. PRESENCE OF COMPLEX REGULATORY FRAMEWORK 15
        3.2.2. MOLECULAR DIAGNOSTIC TESTS ARE HIGHLY PRICED 15
    3.3. KEY OPPORTUNITIES 15
        3.3.1. ADVANCEMENTS IN GENOMICS 15
        3.3.2. GROWTH PROSPECTS IN EMERGING ECONOMIES 15
    3.4. CHALLENGES 15
       3.4.1. TIME CONSUMING IN CASE OF MICRO-ARRAYS TECHNOLOGY BASED DIAGNOSTICS 15
        3.4.2. LACK OF TRAINED PROFESSIONALS TO OPERATE ADVANCED TOOLS 15


CHAP 4. INDUSTRY ANALYSIS 16
    4.1. GLOBAL MOLECULAR DIAGNOSTICS MARKET– PORTER’S FIVE FORCE MODEL 16
    4.2. GLOBAL MOLECULAR DIAGNOSTICS MARKET– PESTEL ANALYSIS 16
    4.3. GLOBAL MOLECULAR DIAGNOSTICS MARKET– GAP ANALYSIS 16


CHAP 5. GLOBAL MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2012-2022 ($ BILLION) 17
    5.1. GLOBAL ONCOLOGY MARKET 2012-2022 ($ BILLION) 17
        5.1.1. GLOBAL BREAST CANCER MARKET 2012-2022 ($ BILLION) 17
        5.1.2. GLOBAL PROSTATE CANCER MARKET 2012-2022 ($ BILLION) 17
        5.1.3. GLOBAL COLORECTAL CANCER MARKET 2012-2022 ($ BILLION) 17
    5.2. GLOBAL GENETIC TESTS MARKET 2012-2022 ($ BILLION) 17
    5.3. GLOBAL INFECTIOUS DISEASES MARKET 2012-2022 ($ BILLION) 17
       5.3.1. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) MARKET 2012-2022 ($ BILLION) 17
        5.3.2. GLOBAL CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) MARKET 2012-2022 ($ BILLION) 17
        5.3.3. GLOBAL HEPATITIS B MARKET 2012-2022 ($ BILLION) 17
        5.3.4. GLOBAL TUBERCULOSIS (TB) MARKET 2012-2022 ($ BILLION) 17
        5.3.5. GLOBAL HEPATITIS C MARKET 2012-2022 ($ BILLION) 17
        5.3.6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) MARKET 2012-2022 ($ BILLION) 17
        5.3.7. GLOBAL HUMAN PAPILLOMAVIRUS (HPV) MARKET 2012-2022 ($ BILLION) 17
        5.3.8. GLOBAL OTHERS MARKET 2012-2022 ($ BILLION) 17
    5.4. GLOBAL MICROBIOLOGY MARKET 2012-2022 ($ BILLION) 17
    5.5. GLOBAL BLOOD SCREENING MARKET 2012-2022 ($ BILLION) 17
    5.6. GLOBAL OTHERS MARKET 2012-2022 ($ BILLION) 17


CHAP 6. GLOBAL MOLECULAR DIAGNOSTICS MARKET BY PRODUCTS & SERVICES 2012-2022 ($ BILLION) 18
    6.1. GLOBAL SOFTWARE & SERVICES MARKET 2012-2022 ($ BILLION) 18
    6.2. GLOBAL REAGENTS MARKET 2012-2022 ($ BILLION) 18
    6.3. GLOBAL INSTRUMENTS MARKET 2012-2022 ($ BILLION) 18


CHAP 7. GLOBAL MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 19
    7.1. GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) MARKET 2012-2022 ($ BILLION) 19
    7.2. GLOBAL HYBRIDIZATION (IN-SITU HYBRIDIZATION & FISH) MARKET 2012-2022 ($ BILLION) 19
    7.3. GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET 2012-2022 ($ BILLION) 19
    7.4. GLOBAL DNA SEQUENCING AND NEXT-GENERATION SEQUENCING MARKET 2012-2022 ($ BILLION) 19
    7.5. GLOBAL MICROARRAYS MARKET 2012-2022 ($ BILLION) 19
    7.6. GLOBAL OTHERS TECHNOLOGIES MARKET 2012-2022 ($ BILLION) 19


CHAP 8. GLOBAL MOLECULAR DIAGNOSTICS MARKET BY END USER 2012-2022 ($ BILLION) 20
    8.1. GLOBAL REFERENCE LABORATORIES MARKET 2012-2022 ($ BILLION) 20
    8.2. GLOBAL HOSPITAL/ACADEMIC LABORATORIES MARKET 2012-2022 ($ BILLION) 20
    8.3. GLOBAL OTHER END USERS MARKET 2012-2022 ($ BILLION) 20


CHAP 9. GLOBAL MOLECULAR DIAGNOSTICS MARKET, REGIONAL OUTLOOK 2012-2022 ($ BILLION) 21
    9.1. GLOBAL MOLECULAR DIAGNOSTICS MARKET BY REGION 2012-2022 ($ BILLION) 21
    9.2. NORTH AMERICA 21
        9.2.1. NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
        9.2.2. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 21
        9.2.3. NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
            9.2.3.1. U.S. 21
                9.2.3.1.1. U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
                9.2.3.1.2. U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
            9.2.3.2. CANADA 21
                9.2.3.2.1. CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
                9.2.3.2.2. CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
    9.3. EUROPE 21
        9.3.1. EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 21
        9.3.2. EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 21
        9.3.3. EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 21
            9.3.3.1. GERMANY 21
                9.3.3.1.1. GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
                9.3.3.1.2. GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
        9.3.3.2. UK 22
            9.3.3.2.1. UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
            9.3.3.2.2. UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
        9.3.3.3. FRANCE 22
            9.3.3.3.1. FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
            9.3.3.3.2. FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
        9.3.3.4. SPAIN 22
            9.3.3.4.1. SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
         9.3.3.4.2. SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
        9.3.3.5. REST OF EUROPE 22
            9.3.3.5.1. RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 22
        9.3.3.5.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 22
    9.4. ASIA PACIFIC 22
        9.4.1. ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 22
     9.4.2. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 22
        9.4.3. ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 22
            9.4.3.1. CHINA 22
                9.4.3.1.1. CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
                9.4.3.1.2. CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
            9.4.3.2. INDIA 23
                9.4.3.2.1. INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
               9.4.3.2.2. INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
            9.4.3.3. JAPAN 23
                9.4.3.3.1. JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
            9.4.3.3.2. JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 23
            9.4.3.4. OTHERS 23
                9.4.3.4.1. OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 23
        9.4.3.4.2. OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 23
        9.5. MIDDLE EAST & AFRICA 23
        9.5.1. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
        9.5.2. MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
    9.6. LATIN AMERICA 23
        9.6.1. LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 23
        9.6.2. LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 23
            9.6.2.1. BRAZIL 23
                9.6.2.1.1. BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
                9.6.2.1.2. BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24
            9.6.2.2. OTHERS 24
                9.6.2.2.1. OTHERS MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 24
               9.6.2.2.2. OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 24


CHAP 10. COMPETITIVE LANDSCAPE 25
    10.1. QIAGEN N.V. 26
        10.1.1. COMPANY OVERVIEW 26
        10.1.2. FINANCIAL PERFORMANCE 26
        10.1.3. PRODUCT BENCHMARKING 26
        10.1.4. STRATEGIC INITIATIVES 26
    10.2. HOLOGIC, INC. 26
        10.2.1. COMPANY OVERVIEW 26
        10.2.2. FINANCIAL PERFORMANCE 26
        10.2.3. PRODUCT BENCHMARKING 26
        10.2.4. STRATEGIC INITIATIVES 26
    10.3. ABBOTT LABORATORIES 26
        10.3.1. COMPANY OVERVIEW 26
        10.3.2. FINANCIAL PERFORMANCE 26
        10.3.3. PRODUCT BENCHMARKING 26
        10.3.4. STRATEGIC INITIATIVES 26
    10.4. ROCHE DIAGNOSTICS 26
        10.4.1. COMPANY OVERVIEW 26
        10.4.2. FINANCIAL PERFORMANCE 26
        10.4.3. PRODUCT BENCHMARKING 26
        10.4.4. STRATEGIC INITIATIVES 26
    10.5. GRIFOLS 26
        10.5.1. COMPANY OVERVIEW 26
        10.5.2. FINANCIAL PERFORMANCE 26
        10.5.3. PRODUCT BENCHMARKING 26
        10.5.4. STRATEGIC INITIATIVES 26
    10.6. BECTON, DICKINSON AND COMPANY 26
        10.6.1. COMPANY OVERVIEW 26
        10.6.2. FINANCIAL PERFORMANCE 27
        10.6.3. PRODUCT BENCHMARKING 27
        10.6.4. STRATEGIC INITIATIVES 27
    10.7. BIOMERIEUX SA 27
        10.7.1. COMPANY OVERVIEW 27
        10.7.2. FINANCIAL PERFORMANCE 27
        10.7.3. PRODUCT BENCHMARKING 27
        10.7.4. STRATEGIC INITIATIVES 27
    10.8. SIEMENS HEALTHCARE 27
        10.8.1. COMPANY OVERVIEW 27
        10.8.2. FINANCIAL PERFORMANCE 27
        10.8.3. PRODUCT BENCHMARKING 27
        10.8.4. STRATEGIC INITIATIVES 27
    10.9. BECKMAN COULTER INC. 27
        10.9.1. COMPANY OVERVIEW 27
        10.9.2. FINANCIAL PERFORMANCE 27
        10.9.3. PRODUCT BENCHMARKING 27
        10.9.4. STRATEGIC INITIATIVES 27
    10.10. CEPHEID INC. 27
        10.10.1. COMPANY OVERVIEW 27
        10.10.2. FINANCIAL PERFORMANCE 27
        10.10.3. PRODUCT BENCHMARKING 27
        10.10.4. STRATEGIC INITIATIVES 27
    10.11. ALERE INC. 27
        10.11.1. COMPANY OVERVIEW 27
        10.11.2. FINANCIAL PERFORMANCE 27
        10.11.3. PRODUCT BENCHMARKING 27
        10.11.4. STRATEGIC INITIATIVES 27
    10.12. BAYER HEALTHCARE 28
        10.12.1. COMPANY OVERVIEW 28
        10.12.2. FINANCIAL PERFORMANCE 28
        10.12.3. PRODUCT BENCHMARKING 28
        10.12.4. STRATEGIC INITIATIVES 28
    10.13. BIO-RAD LABORATORIES ‏ 28
        10.13.1. COMPANY OVERVIEW 28
        10.13.2. FINANCIAL PERFORMANCE 28
        10.13.3. PRODUCT BENCHMARKING 28
        10.13.4. STRATEGIC INITIATIVES 28
    10.14. DANAHER CORPORATION 28
        10.14.1. COMPANY OVERVIEW 28
        10.14.2. FINANCIAL PERFORMANCE 28
        10.14.3. PRODUCT BENCHMARKING 28
        10.14.4. STRATEGIC INITIATIVES 28
    10.15. SYSMEX CORPORATION 28
        10.15.1. COMPANY OVERVIEW 28
        10.15.2. FINANCIAL PERFORMANCE 28
        10.15.3. PRODUCT BENCHMARKING 28
        10.15.4. STRATEGIC INITIATIVES 28

TABLE 1 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY APPLICATION 2012-2022 ($ BILLION) 29
TABLE 2 GLOBAL ONCOLOGY MARKET 2012-2022 ($ BILLION) 29
TABLE 3 GLOBAL BREAST CANCER MARKET 2012-2022 ($ BILLION) 29
TABLE 4 GLOBAL PROSTATE CANCER MARKET 2012-2022 ($ BILLION) 29
TABLE 5 GLOBAL COLORECTAL CANCER MARKET 2012-2022 ($ BILLION) 29
TABLE 6 GLOBAL GENETIC TESTS MARKET 2012-2022 ($ BILLION) 29
TABLE 7 GLOBAL INFECTIOUS DISEASES MARKET 2012-2022 ($ BILLION) 29
TABLE 8 GLOBAL HUMAN IMMUNODEFICIENCY VIRUS (HIV) MARKET 2012-2022 ($ BILLION) 29
TABLE 9 GLOBAL CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAE (CT/NG) MARKET 2012-2022 ($ BILLION) 29
TABLE 10 GLOBAL HEPATITIS B MARKET 2012-2022 ($ BILLION) 29
TABLE 11 GLOBAL TUBERCULOSIS (TB) MARKET 2012-2022 ($ BILLION) 29
TABLE 12 GLOBAL HEPATITIS C MARKET 2012-2022 ($ BILLION) 29
TABLE 13 GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) MARKET 2012-2022 ($ BILLION) 29
TABLE 14 GLOBAL HUMAN PAPILLOMAVIRUS (HPV) MARKET 2012-2022 ($ BILLION) 29
TABLE 15 GLOBAL OTHERS MARKET 2012-2022 ($ BILLION) 29
TABLE 16 GLOBAL MICROBIOLOGY MARKET 2012-2022 ($ BILLION) 29
TABLE 17 GLOBAL BLOOD SCREENING MARKET 2012-2022 ($ BILLION) 29
TABLE 18 GLOBAL OTHERS MARKET 2012-2022 ($ BILLION) 29
TABLE 19 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY PRODUCTS & SERVICES 2012-2022 ($ BILLION) 29
TABLE 20 GLOBAL SOFTWARE & SERVICES MARKET 2012-2022 ($ BILLION) 29
TABLE 21 GLOBAL REAGENTS MARKET 2012-2022 ($ BILLION) 29
TABLE 22 GLOBAL INSTRUMENTS MARKET 2012-2022 ($ BILLION) 30
TABLE 23 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY 2012-2022 ($ BILLION) 30
TABLE 24 GLOBAL ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT) MARKET 2012-2022 ($ BILLION) 30
TABLE 25 GLOBAL HYBRIDIZATION (IN-SITU HYBRIDIZATION & FISH) MARKET 2012-2022 ($ BILLION) 30
TABLE 26 GLOBAL POLYMERASE CHAIN REACTION (PCR) MARKET 2012-2022 ($ BILLION) 30
TABLE 27 GLOBAL DNA SEQUENCING AND NEXT-GENERATION SEQUENCING MARKET 2012-2022 ($ BILLION) 30
TABLE 28 GLOBAL MICROARRAYS MARKET 2012-2022 ($ BILLION) 30
TABLE 29 GLOBAL OTHERS MARKET 2012-2022 ($ BILLION) 30
TABLE 30 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY END USER 2012-2022 ($ BILLION) 30
TABLE 31 GLOBAL REFERENCE LABORATORIES MARKET 2012-2022 ($ BILLION) 30
TABLE 32 GLOBAL HOSPITAL/ACADEMIC LABORATORIES MARKET 2012-2022 ($ BILLION) 30
TABLE 33 GLOBAL OTHER END USERS MARKET 2012-2022 ($ BILLION) 30
TABLE 34 GLOBAL MOLECULAR DIAGNOSTICS MARKET, REGIONAL OUTLOOK 2012-2022 ($ BILLION) 30
TABLE 35 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY REGION 2012-2022 ($ BILLION) 30
TABLE 36 NORTH AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 37 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 30
TABLE 38 NORTH AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 39 U.S. MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 30
TABLE 40 U.S. MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 30
TABLE 41 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 42 CANADA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 43 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 44 EUROPE MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 31
TABLE 45 EUROPE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 46 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 47 GERMANY MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 48 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 49 UK MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 50 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 51 FRANCE MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 52 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 53 SPAIN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 31
TABLE 54 RUSSIA MARKET ESTIMATES AND FORECAST2012-2022($BILLION) 31
TABLE 55 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 31
TABLE 56 ASIA PACIFIC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 31
TABLE 57 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY REGION 2012-2022 ($ BILLION) 31
TABLE 58 ASIA PACIFIC MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32
TABLE 59 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
TABLE 60 CHINA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32
TABLE 61 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
TABLE 62 INDIA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32
TABLE 63 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
TABLE 64 JAPAN MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($BILLION) 32
TABLE 65 OTHER MARKET ESTIMATES AND FORECASTS 2012-2022($BILLION) 32
TABLE 66 OTHER MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022($BILLION) 32
TABLE 67 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
TABLE 68 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32
TABLE 69 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
TABLE 70 LATIN AMERICA MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32
TABLE 71 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
TABLE 72 BRAZIL MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32
TABLE 73 OTHERS MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 32
TABLE 74 OTHERS MARKET ESTIMATES AND FORECAST BY APPLICATION 2012-2022 ($ BILLION) 32

FIGURE 1 MARKET SHARE BY REGIONS 28
FIGURE 2 UNITED STATES MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
FIGURE 3 CANADA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
FIGURE 4 EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
FIGURE 5 GERMANY MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 28
FIGURE 6 UK MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 7 FRANCE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 8 SPAIN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 9 REST OF EUROPE MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 10 APAC MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 11 CHINA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 12 INDIA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 13 JAPAN MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 14 MIDDLE EAST & AFRICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 15 LATIN AMERICA MARKET ESTIMATES AND FORECAST 2012-2022 ($ BILLION) 29
FIGURE 16 BRAZIL MARKET ESTIMATES AND FORECAST 2012-2022($BILLION) 29

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)